<DOC>
	<DOCNO>NCT00496093</DOCNO>
	<brief_summary>To describe safety , tolerability immunogenicity pneumovax 23 ( V110 ) healthy adult India .</brief_summary>
	<brief_title>Safety , Tolerability Immunogenicity Pneumovax 23 Healthy Adults India ( V110-011 )</brief_title>
	<detailed_description>This open-label non-randomized study ass safety immunogenicity PNEUMOVAXTM 23 healthy adult India . The participant enrol study healthy Indian adult , 50 year age old , prior history receive pneumococcal vaccination ( 14-valent 23-valent ) prior history Pneumococcal disease . All participant enrol study receive one 0.5 mL dose PNEUMOVAXTM 23 intramuscular ( deltoid ) injection Day 1 . Serum sample obtain prior vaccination Day 1 Day 28 ( +/-7 day ) postvaccination . The duration participation participant approximately one month , study completion Day 28 postvaccination bleed return Vaccination Report Card ( VRC ) . Enrollment complete within approximately 2 month . The last postvaccination blood sample collect within 3 month study initiation .</detailed_description>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy indian adult 50 year age In good health ; underlie chronic illness must document stable condition Signed date informed consent prior receipt study vaccine Functional anatomic asplenia History auto immune disease Hypersensitivity component study vaccine , include phenol Known suspect immune dysfunction , include person congenital immunodeficiency Prior vaccination pneumococcal vaccine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>